Compound 22 (TAAR1 antagonist)
Overview[edit | edit source]
Compound 22 is a chemical compound known for its role as a selective antagonist of the TAAR1 receptor. TAAR1 is a G protein-coupled receptor (GPCR) that is activated by trace amines, which are endogenous compounds structurally similar to monoamine neurotransmitters. Compound 22 is of interest in the field of neuropharmacology due to its potential implications in modulating monoaminergic systems.
Chemical Properties[edit | edit source]
Compound 22 is characterized by its specific chemical structure, which allows it to selectively bind to and inhibit the activity of the TAAR1 receptor. The chemical structure of Compound 22 is depicted in the adjacent image. This structural specificity is crucial for its function as an antagonist, as it prevents the receptor from being activated by its natural ligands.
Mechanism of Action[edit | edit source]
As a TAAR1 antagonist, Compound 22 functions by binding to the TAAR1 receptor and blocking its activation by endogenous trace amines. This blockade can modulate the activity of monoaminergic systems, which include neurotransmitters such as dopamine, serotonin, and norepinephrine. By inhibiting TAAR1, Compound 22 may influence various physiological and behavioral processes regulated by these neurotransmitters.
Potential Applications[edit | edit source]
Research into Compound 22 and other TAAR1 antagonists is ongoing, with potential applications in the treatment of various neuropsychiatric disorders. TAAR1 has been implicated in the regulation of mood, cognition, and reward, suggesting that antagonists like Compound 22 could be useful in conditions such as depression, schizophrenia, and substance use disorders.
Research and Development[edit | edit source]
The development of Compound 22 and similar compounds involves extensive pharmacological testing to determine their efficacy, selectivity, and safety profiles. Studies often focus on the compound's ability to modulate monoaminergic activity in animal models, with the aim of translating these findings into potential therapeutic applications in humans.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
